Clinical Implications of Size of Cavities in Patients With Nontuberculous Mycobacterial Pulmonary Disease: A Single-Center Cohort Study

Hye-Rin Kang  
VHS Medical Center: Seoul Veterans Hospital

Eui Jin Hwang  
Seoul National University College of Medicine

Sung A Kim  
Seoul National University Hospital

Sun Mi Choi  
Seoul National University College of Medicine

Jinwoo Lee  
Seoul National University College of Medicine

Chang-Hoon Lee  
Seoul National University College of Medicine

Jae-Joon Yim  
Seoul National University College of Medicine

Nakwon Kwak (n.kwak@snu.ac.kr)  
Seoul National University College of Medicine

Research

Keywords: nontuberculous mycobacteria, cavity, outcome, mortality

Posted Date: December 10th, 2020

DOI: https://doi.org/10.21203/rs.3.rs-124209/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background

The presence of cavities is a poor prognostic factor in patients with nontuberculous mycobacterial pulmonary disease (NTM-PD). However, little is known about the characteristics of such cavities and their impact on clinical outcomes. The aim of this study is to investigate the size of cavities and their implications on treatment outcomes and mortality in patients with NTM-PD.

Methods

We included patients diagnosed with NTM-PD at Seoul National University Hospital between 1 January 2007 and 31 December 2018. We measured the size of cavities on chest computed tomography scans performed at the time of diagnosis, and used multivariable logistic regression and Cox-proportional hazards regression analysis to investigate the impact of these measurements on treatment outcomes and mortality.

Results

The study cohort comprised 421 patients (non-cavitary, n=329; cavitary, n=92) with NTM-PD. During a median follow-up period of 49 months, 118 (35.9%) of the 329 patients with non-cavitary and 64 (69.6%) of the 92 patients with cavitary NTM-PD received antibiotic treatment. Cavities >2 cm were associated with worse treatment outcomes (adjusted odds ratio, 0.38; 95% confidence interval [CI], 0.16–0.86) and higher mortality (adjusted hazard ratio, 2.50; 95% CI, 1.04–6.02), while there was no difference in treatment outcomes and mortality between patients with cavities <2 cm and patients with non-cavitary NTM-PD.

Conclusions

Clinical outcomes are different according to the size of cavities in patients with cavitary NTM-PD; thus the measurement of the size of cavities could help in making clinical decisions.

Background

Nontuberculous mycobacteria (NTM) are ubiquitous micro-organisms that can be isolated from the environment, including soil and water [1]. The most common clinical manifestation of human NTM infection is pulmonary disease (PD) [2]. The burden of NTM-PD is currently increasing globally. Between 2008 and 2016, the annual incidence of NTM infection increased from 6.0 cases/100,000 person-years to 19.0 cases/100,000 person-years in South Korea [3]. Similar increases in incidence have also been reported in Japan [4], the USA [5], and Europe [6].

NTM-PD can be classified into clinical phenotypes according to radiographic presentations: nodular bronchiectatic (NB) and fibrocavitary (FC). NB types can be sub-classified into non-cavitary and cavitary
The presence of cavities is reportedly associated with a worse prognosis [9]. The mortality risk is highest for the FC form, followed by cavitary NB, and non-cavitary NB forms. Similarly, the responses of cavitary NB and FC forms to antibiotic treatment are worse than those of non-cavitary NB forms [7, 8].

Because of their prognostic impact, it is recommended that patients with cavities commence antibiotic treatment, rather than be managed by watchful waiting [2]. Furthermore, more aggressive treatment, including parenteral agents, is also recommended for such patients [10, 11]. The presence of cavities in itself has been considered an important prognostic factor; however, the clinical course may vary according to the radiographic features of such cavities [12]. Nevertheless, the impact on treatment outcomes and mortality of radiographic features such as size of cavities has rarely been reported. In this study, we elucidated the relationships between the size of cavities and treatment outcomes and mortality in patients with NTM-PD.

**Methods**

**Study design and subjects**

This retrospective study included patients diagnosed with NTM-PD between 1 January 2007 and 31 December 2018, at Seoul National University Hospital. The diagnostic criteria for NTM-PD were as proposed in the American Thoracic Society/European Respiratory Society/European Society of Clinical Microbiology and Infectious Diseases/Infectious Diseases Society of America clinical practice guidelines [2]. Patients who were at least 18 years old and had chest computed tomography (CT) scans at the time of diagnosis were included. Patients who were lost-to-follow-up within a year after NTM-PD diagnosis were excluded from the analysis. Some of the patients were included in a previously reported prospective study that was launched on 1 July 2011 (NCT01616745) [13, 14]. This study was conducted in accordance with the tenets of the amended Declaration of Helsinki; the Institutional Review Board of Seoul National University Hospital approved the study protocol (IRB No. 2001-047-1092).

**Baseline and follow-up data collection**

The clinical and laboratory data at the time of NTM-PD diagnosis, including age, sex, body mass index (BMI), smoking history, comorbidities (chronic obstructive pulmonary disease, diabetes mellitus, and malignancy), sputum smear results, and the species of causative organisms, were collected for all patients. The species were identified by 16S rRNA and rpoB gene sequencing analysis [15–17]. Radiographic findings (presence of cavities and their size) were interpreted by three reviewers (one chest radiologist and two pulmonologists). The presence of a cavity was defined as a gas-filled space presenting as a lucent or as low-attenuated space within pulmonary consolidation [18]. Cavity size was determined by measuring the longest diameter on axial images. Three measurement was made and the average values used for analysis. Any discrepancies between the reviewers were resolved by discussion. The patients were classified according to the presence and size of cavities.
After diagnosis with NTM-PD, the patients were followed up every 3–6 months. At each follow-up visit, the patient submitted a sputum specimen for an acid-fast bacilli smear test and mycobacterial culture. Chest CT scans were usually performed at intervals of 2 years in patients being managed by watchful waiting and intervals of 6 months for patients on antibiotic treatment. Timing of initiation of antimycobacterial treatment was decided at the discretion of the on-duty physician on the basis of symptoms and radiographic changes. After initiation of treatment, the patients were followed up every 4–8 weeks.

**Clinical outcomes**

Clinical outcomes were assessed according to the criteria suggested by an NTM-NET consensus statement [19]. Culture conversion was defined as at least three consecutive negative mycobacterial cultures from sputum samples collected at least 4 weeks apart. Microbiological cure was defined as maintenance of multiple consecutive negative cultures of respiratory samples from after culture conversion until the end of anti-mycobacterial treatment. Patient death was confirmed using the database of the Ministry of the Interior and Safety, South Korea.

**Statistical analysis**

Data are presented as median values with interquartile ranges (IQRs) for continuous variables and as proportions for categorical variables. Wilcoxon's rank-sum test, Kruskal–Wallis test, and Fisher's exact test were used to compare continuous and categorical variables. Multivariate logistic regression analysis was used to identify factors associated with the presence of cavities in patients with NTM-PD. Kaplan–Meier analysis with log-rank test and Cox-proportional hazards regression were performed to analyse survival data. Variables with a P-value < 0.2 in univariate analysis were used in the multivariate analysis. A P-value < 0.05 was considered to denote statistical significance. All statistical analyses were performed with STATA 13.1 (College Station, TX, USA).

**Results**

**Baseline characteristics of patients with NTM-PD**

The study cohort comprised 421 patients with NTM-PD. Their median age was 64 years (IQR, 57–73 years) and 271 (64.4%) were women. Non-cavitary NTM-PD was diagnosed in 329 patients, the remaining 92 having at least one cavity at the time of diagnosis. The distribution of mycobacterial species did not differ significantly between non-cavitary NTM-PD (M. avium complex [MAC] 72.0%, M. abscessus complex 18.2% and others 9.8%) and cavitary NTM-PD (MAC 67.4%, M. abscessus complex 23.9% and others 8.7%) (P = 0.464). The median diameter of the cavities was 1.8 cm (IQR, 1.2–2.8 cm) and 53 patients (57.6%) had a single cavity. Median size (2 cm- rounded up) was used for further analysis, as described below.

A higher proportion of patients with cavitary NTM-PD (51.1%) than with non-cavitary NTM-PD (36.2%) had a history of previous pulmonary tuberculosis (TB). Positive sputum smears were also more prevalent
in patients with cavitary NTM-PD (29.4% versus 17.3%, \( P = 0.017 \)). Patients with cavitary NTM-PD were younger (\( P = 0.045 \)) and their BMI was lower (\( P = 0.003 \)) than those of patients without cavitary NTM-PD. Further, the distribution of comorbidities and NTM species did not differ between these two groups (Table 1).

### Table 1
Baseline characteristics of 421 patients with nontuberculous mycobacterial pulmonary disease according to the presence of a cavity

|                        | Patients without cavities (n = 329) | Patients with cavities (n = 92) | \( P \)-value |
|------------------------|------------------------------------|--------------------------------|---------------|
| Age, years, median (IQR) | 65 (58–73)                         | 63 (55–72)                     | 0.045         |
| Sex, female (%)         | 216 (65.7)                         | 55 (59.8)                      | 0.325         |
| BMI, kg/m\(^2\), median (IQR) | 21.1 (19.6–22.6)                 | 20.1 (18.6–21.9)               | 0.003         |
| Former or current smoker, n (%) | 79 (24.0)                       | 22 (23.9)                      | 0.984         |
| History of pulmonary tuberculosis | 119 (36.2)                       | 47 (51.1)                      | 0.011         |
| Comorbidities, n (%)    |                                    |                                |               |
| Diabetes mellitus       | 21 (6.4)                           | 11 (12.0)                      | 0.116         |
| COPD                   | 24 (7.3)                           | 10 (10.9)                      | 0.281         |
| Malignancy             | 18 (5.5)                           | 6 (6.5)                        | 0.799         |
| Sputum smear positivity, n (%) | 57 (17.3)                       | 27 (29.4)                      | 0.017         |
| Causative organism, n (%) |                                    |                                | 0.464         |
| \( M. \text{avium} \) complex | 237 (72.0)                       | 62 (67.4)                      |               |
| \( M. \text{abscessus} \) complex | 60 (18.2)                       | 22 (23.9)                      |               |
| Others                 | 32 (9.8)                           | 8 (8.7)                        |               |

Abbreviations: IQR, interquartile range; BMI, body mass index; COPD, chronic obstructive pulmonary disease.
Clinical course of NTM-PD according to the size of cavities

During a median follow-up of 49 months (IQR, 31–70 months), 239 patients (211 with non-cavitary and 28 with cavitary NTM-PD) were managed by watchful waiting and required no treatment. Of these patients, a higher proportion had non-cavitary (64.1%) than cavitary NTM-PD (30.4%) (P < 0.001). Sixty-six of the 211 (31.3%) patients with non-cavitary NTM-PD being managed by watchful waiting achieved culture conversion without treatment, as did 12 of the 28 (42.9%) patients with cavitary NTM-PD (8 patients with cavities ≤ 2 cm and 4 patients with cavities > 2 cm) (P = 0.396).

During the study period, 118 (35.9%) of the 329 patients with non-cavitary NTM-PD and 64 (69.6%) of the 92 with cavitary NTM-PD received antibiotic treatment. When patients were classified according to cavity size, those with cavities > 2 cm (75.0%) were the most likely to require antibiotic treatment, followed by patients with cavities ≤ 2 cm (64.6%), and patients without cavities (35.9%) (P < 0.001).

The proportion of patients who achieved microbiological cure was the lowest among patients with cavities > 2 cm (36.4%), followed by those with cavities ≤ 2 cm (48.4%), and those without cavities (60.2%) (P = 0.045). Finally, cavities > 2 cm (adjusted odds ratio, 0.38; 95% confidence interval [CI], 0.16–0.86) were inversely associated with microbiological cure according to multivariable logistic regression. However, small cavities (≤ 2 cm) (P = 0.207) did not affect treatment outcomes (Table 3).
Table 3
Factors associated with microbiological cure in patients with nontuberculous mycobacterial pulmonary disease

|                                      | Univariate analysis |          |          | Multivariate analysis |          |
|--------------------------------------|---------------------|----------|----------|-----------------------|----------|
|                                      | OR (95% CI)         | P-value  | OR (95% CI) | P-value              |
| Age, years                           | 0.98 (0.95-1.00)    | 0.162    | 0.97 (0.94–1.01) | 0.112              |
| Sex, male                            | 0.76 (0.41–1.41)    | 0.380    |            |                       |
| BMI, kg/m²                           | 1.08 (0.96–1.21)    | 0.204    |            |                       |
| History of pulmonary tuberculosis   | 1.09 (0.74–1.60)    | 0.676    |            |                       |
| Comorbidities, n (%)                 |                     |          |          |                       |
| Diabetes mellitus                    | 1.00 (0.32–3.10)    | 0.999    |            |                       |
| COPD                                 | 0.66 (0.25–1.75)    | 0.402    |            |                       |
| Malignancy                           | 1.30 (0.36–4.79)    | 0.689    |            |                       |
| Causative organism, n (%)            |                     |          |          |                       |
| *M. avium* complex                   | Reference           |          |          |                       |
| *M. abscessus* complex               | 1.35 (0.65–2.81)    | 0.415    |            |                       |
| Sputum smear positivity              | 0.43 (0.22–0.85))   | 0.014    | 0.47 (0.24–0.93) | 0.031              |
| Size of cavity                       |                     |          |          |                       |
| absence of cavity                    | Reference           |          |          |                       |
| ≤ 2 cm sized                         | 0.62 (0.28–1.37)    | 0.240    | 0.59 (0.26–1.33) | 0.207              |
| > 2 cm sized                         | 0.38 (0.17–0.84)    | 0.017    | 0.38 (0.16–0.86) | 0.021              |

Abbreviations: OR, odds ratio; CI, confidence interval; BMI, body mass index; COPD, chronic obstructive pulmonary disease.

Factors associated with mortality in patients with NTM-PD

During the study period, 32 of 421 (7.6%) patients died, comprising 21 of 329 (6.4%) with non-cavitary and 11 of 92 (12.0%) with cavitary NTM-PD. According to the log-rank test, there was a significant difference in mortality between patients with cavities > 2 cm and patients with non-cavitary NTM-PD (P = 0.003). However, there was no difference in mortality between patients with cavities ≤ 2 cm and patients with non-cavitary NTM-PD (P = 0.897) (Fig. 1). According to multivariable Cox-proportional hazards regression analysis, patients with cavities > 2 cm had a higher risk of death (adjusted hazard ratio, 2.50; 95% CI, 1.04–6.02) than did patients with non-cavitary NTM-PD (Table 4).
Table 4
Factors associated with mortality in patients with nontuberculous mycobacterial pulmonary disease

|                                | Univariate analysis |          | Multivariate analysis |          |
|--------------------------------|---------------------|----------|-----------------------|----------|
|                                | HR (95% CI)         | P-value  | HR (95% CI)          | P-value  |
| Age, year                      | 1.06 (1.02–1.10)    | 0.001    | 1.05 (1.01–1.09)     | 0.031    |
| Sex, male                      | 3.91 (1.80–8.47)    | 0.001    | 3.83 (1.59–9.26)     | 0.003    |
| BMI, kg/m²                     | 0.86 (0.75–0.99)    | 0.030    | 0.83 (0.71–0.96)     | 0.013    |
| History of pulmonary tuberculosis | 1.44 (0.72–2.88)    | 0.305    |                      |          |
| Diabetes mellitus              | 4.23 (1.89–9.44)    | < 0.001  | 4.08 (1.55–10.8)     | 0.004    |
| COPD                           | 2.87 (1.33–6.17)    | 0.007    | 0.82 (0.32–2.09)     | 0.669    |
| Malignancy                     | 2.50 (0.96–6.52)    | 0.062    | 5.44 (1.81–16.3)     | 0.003    |
| Causative organism             |                     |          |                      |          |
| *M. avium* complex             | reference           |          |                      |          |
| *M. abscessus* complex         | 1.67 (0.75–3.72)    | 0.210    |                      |          |
| Sputum smear positivity        | 1.82 (0.84–3.94)    | 0.128    | 2.34 (0.98–5.62)     | 0.056    |
| Size of cavity                 |                     |          |                      |          |
| absence of cavity              | Reference           |          |                      |          |
| ≤ 2 cm sized                   | 0.89 (0.21–3.81)    | 0.879    | 0.89 (1.89–4.19)     | 0.882    |
| > 2 cm sized                   | 3.09 (1.40–6.79)    | 0.005    | 2.50 (1.04–6.02)     | 0.041    |

Abbreviations: HR, hazard ratio; CI, confidence interval; BMI, body mass index; COPD, chronic obstructive pulmonary disease.

Discussion

In this study, we analysed the clinical course of 421 patients with NTM-PD according to the size of cavities at the time of diagnosis. We found that patients with cavities > 2 cm had worse treatment outcomes than did patients with non-cavitary NTM-PD. In contrast, patients with cavities ≤ 2 cm had treatment outcomes that were comparable to those of patients with non-cavitary NTM-PD. Our results support the need for planning treatment according to the radiographic features of cavities in patients with NTM-PD.

The presence of cavities in patients with NTM-PD has been recognised as an indicator of poor prognosis [9]. Cavities are associated with unfavourable treatment outcomes, including higher mortality [20, 21]. Cavity formation has been found more commonly in patients who do not respond to treatment than in
those with culture conversion [21]. Additionally, the presence of a cavity increases the risk of all-cause mortality in patients with *Mycobacterium avium* complex pulmonary disease (MAC-PD) [20]. Moreover, large cavities are strongly associated with disease progression [12]. However, the impact of detailed differentiation based on radiographic findings has not been reported.

NTM-PD has been classified into NB and FC types [11]. However, it is sometimes difficult to clearly differentiate between these types. Bronchiectasis co-exists with cavities in most patients with NTM-PD [22]. Pathologic findings on examination of specimens from patients with NTM-PD has suggested that peri-bronchial nodules evolve into cavities [22]. Another cohort study found that cavities develop over time, even in the NB form of MAC-PD [23]. If we assume that bronchiectasis and cavities are on the same disease spectrum, NTM-PD could be differentiated initially by the presence of one or more cavities and the extent of those cavities. In our study, we classified NTM-PD according to the presence and size of cavities.

Patients with cavitary NTM-PD more frequently received antibiotic treatment than those without cavities. When the cavity was > 2 cm in diameter, the treatment outcome was unfavourable. The mortality rate was also higher in patients with cavities > 2 cm. However, the cavities ≤ 2 cm did not affect the clinical outcomes. In our study, cavities only had an impact on the prognosis of patients with NTM-PD when they were > 2 cm.

Cavitation in the lung results from a number of pathological processes, including suppurative, caseous, and ischemic necrosis [24]. In NTM-PD, cavitation occurs in patients with more extensive disease and the cavities contain numerous organisms [24, 25]. Drugs penetrate cavities poorly and sub-therapeutic drug concentrations in these lesions can lead to acquired drug resistance [26]. These factors explain the worse outcomes of patients with NTM-PD with cavities > 2 cm.

Interestingly, in our study, a small cavity (< 2 cm) was not associated with poor prognosis. Large cavities were more prevalent in progressive cavitary NTM-PD [12]. Thus, the favourable outcomes of small cavities in patients with NTM-PD may be attributable to slow disease progression. Another possible explanation is that, once such cavities have been detected, more careful monitoring and aggressive treatment are adopted, resulting in favourable outcomes given that such patients respond better to treatment than do those with larger cavities.

Our findings suggest the need for more detailed planning of treatment for cavitary NTM-PD according to the characteristics of the cavities. Recent guidelines recommend initiation of antibiotic treatment for NTM-PD rather than watchful waiting, especially when sputum smears are positive for acid-fast bacilli or when there is evidence of cavitary lung disease [2]. Parenteral agents are recommended for cavitary disease in patients with MAC-PD, [2, 10]. Our results suggest a more complex treatment strategy for patients with cavitary NTM-PD. In patients with > 2 cm, immediate and intensive treatment is indicated. If the cavity size is ≤ 2 cm, whether or not to treat should be decided on the basis of the overall clinical situation, under the premise that watchful follow-up is guaranteed.
Retrospective studies from South Korea have shown that the condition of about 40% of patients with non-cavitary NB NTM-PD remains stable when they are observed without treatment [27, 28]. Spontaneous culture conversion occurs in 35–50% of untreated patients [27, 28]. In our study, spontaneous conversion was achieved in 12 of 28 patients (42.9%) with cavitary NTM-PD who had been undergoing regular monitoring without initiation of treatment. Thus, when an immediate initiation of treatment is not available, watchful waiting might be a valid management option for patients with small cavities, once close monitoring is ensured.

This study has some limitations. First, the causes of the cavities could not be determined. Although the cavities were suggested to be the manifestation of NTM-PD, we could not completely exclude the possibility of combined fungal infection or other chronic infection [29, 30]. Second, we did not use the classical classification of NB or FC forms in our analysis. In fact, cavities frequently co-exist with bronchiectasis and some of cavities develop from bronchiectatic changes [22]. It is difficult to distinguish between non-cavitary NB, cavitary NB, and FC types in some patients. In contrast, a classification based on size may be easier to use.

**Conclusions**

In conclusion, the clinical outcomes of patients with cavitary NTM-PD differ according to the size of cavities. A cavity > 2 cm in size in patients with NTM-PD is associated with unfavourable treatment outcomes and higher mortality, whereas cavities ≤ 2 cm do not affect the prognosis. The radiographic features of cavities could help clinicians to decide whether to initiate treatment or not.

**Abbreviations**

aOR = adjusted odds ratio  
BMI = body mass index  
CT = computed tomography  
FC = fibrocavitary  
IQR = interquartile range  
NB = nodular bronchiectatic  
NTM = nontuberculous mycobacteria  
NTM = pulmonary disease  

**Declarations**
Ethics declarations

Ethics approval and consent to participate

Ethics approval was obtained, and consent was waived by the Institutional Review Board of Seoul National University Hospital approved the study protocol (IRB No. 2001-047-1092).

Consent for publication

Not applicable.

Availability of data and materials

The datasets used are available from the corresponding author on reasonable request.

Competing interests

The authors have no conflict of interest to declare.

Funding

This work was supported by a VHS Medical Center Research Grant, Republic of Korea (Grant number VHSMC20047).

Authors’ contribution

The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors, were fully responsible for all content, and were involved at all stages of manuscript development. HRK and NK designed the study and protocol. HRK, EJH and NK did the data analysis. HRK, JJY and NK wrote the initial draft of the manuscript and all authors were involved at all stages of critical revision of manuscript. All the authors read and approved the final manuscript.

Acknowledgments

Not applicable

Authors’ information

Affiliations

Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea

Sun Mi Choi, Jinwoo Lee, Chang-Hoon Lee, Jae-Joon Yim, Nakwon Kwak
Division of Pulmonary Medicine, Department of Internal Medicine, Veterans Health Service Medical Center, Seoul, South Korea

Hye-Rin Kang

Department of Radiology and Institute of Radiation Medicine, Seoul National University College of Medicine, Seoul, South Korea

Eui Jin Hwang

Clinical Trials Center, Seoul National University Hospital, Seoul, South Korea

Sung A Kim

References

1. Falkinham JO. Current epidemiologic trends of the nontuberculous mycobacteria (NTM). Current environmental health reports 2016, 3:161-167. https://doi.org/10.1007/s40572-016-0086-z

2. Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace RJ, Jr., Andrejak C, Böttger EC, Brozek J, Griffith DE, Guglielmetti L, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Clin Infect Dis, 2020 Aug 15;71(4):905-913. https://doi.org/10.1093/cid/ciaa1125

3. Lee H, Myung W, Koh W-J, Moon SM, Jhun BW. Epidemiology of nontuberculous mycobacterial infection. South Korea, 2007-2016. Emerg Infect Dis 2019, 25:569. http://doi.org/10.3201/eid2503.181597

4. Namkoong H, Kurashima A, Morimoto K, Hoshino Y, Hasegawa N, Ato M, Mitarai S. Epidemiology of pulmonary nontuberculous mycobacterial disease, Japan. Emerg Infect Dis. 2016 Jun;22(6):1116-7. http://doi.org/10.3201/eid2206.151086.

5. Henkle E, Hedberg K, Schafer S, Novosad S, Winthrop KL. Population-based incidence of pulmonary nontuberculous mycobacterial disease in Oregon 2007 to 2012. Ann Am Thorac Soc. 2015 May;12(5):642-7. http://doi.org/10.1513/AnnalsATS.201412-559OC.

6. Wagner D, Lipman M, Cooray S, Ringshausen FC, Morimoto K, Koh W-J, Thomson R. Global Epidemiology of NTM Disease (Except Northern America) In: Griffith D. (eds) Nontuberculous Mycobacterial Disease. Respiratory Medicine. Humana Press, Cham. 2019: 163-260 https://doi.org/10.1007/978-3-319-93473-0_8

7. Koh W-J, Moon SM, Kim S-Y, Woo M-A, Kim S, Jhun BW, Park HY, Jeon K, Huh HJ, Ki C-S. Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype. 2017 Sep 27;50(3):1602503. http://doi.org/10.1183/13993003.02503-2016

8. Jhun BW, Moon SM, Jeon K, Kwon OJ, Yoo H, Carriere KC, Huh HJ, Lee NY, Shin SJ, Daley CL. Prognostic factors associated with long-term mortality in 1445 patients with nontuberculous
mycobacterial pulmonary disease: a 15-year follow-up study. Eur Respir 2020 Jan 2;55(1):1900798. http://doi.org/ 10.1183/13993003.00798-2019

9. Kim H-J, Kwak N, Hong H, Kang N, Im Y, Jhun BW, Yim J-J. BACES Score for Predicting Mortality in Nontuberculous Mycobacterial Pulmonary Disease. Am J Respir Crit Care Med 2020 Jul 28. http://doi.org/ 10.1164/rccm.202004-1418OC

10. Haworth CS, Banks J, Capstick T, Fisher AJ, Gorsuch T, Laurenson IF, Leitch A, Loebinger MR, Milburn HJ, Nightingale M et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax 2017 Nov;72(Suppl 2):ii1-ii64. http://doi.org/10.1136/thoraxjnl-2017-210927

11. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huit G, lademarco MF, An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007 Feb 15 175:367-416. http://doi.org/10.1164/rccm.200604-571ST.

12. Oshitani Y, Kitada S, Edahiro R, Tsujino K, Kagawa H, Yoshimura K, Miki K, Miki M, Kida H. Characteristic chest CT findings for progressive cavities in Mycobacterium avium complex pulmonary disease: a retrospective cohort study. Respir Res 2020, Jan 8;21(1):10. http://doi.org/10.1186/s12931-020-1273-x.

13. Park J, Cho J, Lee C-H, Han SK, Yim J-J. Progression and treatment outcomes of lung disease caused by Mycobacterium abscessus and Mycobacterium massiliense. 2017 Feb 1;64(3):301-308. http://doi.org/10.1093/cid/ciw723

14. Kwak N, Kim SA, Choi SM, Lee J, Lee C-H, Yim J-J. Longitudinal changes in health-related quality of life according to clinical course among patients with non-tuberculous mycobacterial pulmonary disease: a prospective cohort study. BMC Pulm Med 2020 May 7;20(1):126. http://doi.org/10.1186/s12890-020-1165-3

15. Clinical, Institute LS. Interpretive Criteria for Identification of Bacteria and Fungi by DNA Target Sequencing: Approved Guideline, MM18-A. CLSI; Wayne, PA; 2008.

16. Kim B-J, Lee S-H, Lyu M-A, Kim S-J, Bai G-H, Kim S-J, Chae G-T, Kim E-C, Cha C-Y, Kook Y-H. Identification of mycobacterial species by comparative sequence analysis of the RNA polymerase gene (rpoB). J Clin Microbiol 1999 Jun;37(6):1714-20. http://doi.org/10.1128/JCM.37.6.1714-1720.1999

17. Salah IB, Adekambi T, Raoult D, Drancourt M. rpoB sequence-based identification of Mycobacterium avium complex species. Microbiology 2008 Dec;154(Pt 12):3715-3723. http://doi.org/10.1099/mic.0.2008/020164-0

18. Hansell DM, Bankier AA, MacMahon H, McLoud TC, Muller NL, Remy J. Fleischner Society: glossary of terms for thoracic imaging. Radiology 2008, 246(3):697-722. http://doi.org/10.1148/radiol.2462070712

19. Van Ingen J, Aksamit T, Andrejak C, Böttger EC, Cambau E, Daley CL, Griffith DE, Guglielmetti L, Holland SM, Huit GA. Treatment outcome definitions in nontuberculous mycobacterial pulmonary
disease: an NTM-NET consensus statement. Eur Respir J. 2018 Mar 22;51(3):1800170. http://doi.org/ 10.1183/13993003.00170-2018

20. Hayashi M, Takayanagi N, Kanauchi T, Miyahara Y, Yanagisawa T, Sugita Y. Prognostic factors of 634 HIV-negative patients with Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2012 Mar 1;185(5):575-83. http://doi.org/ 10.1164/rccm.201107-1203OC

21. Kuroishi S, Nakamura Y, Hayakawa H, Shirai M, Nakano Y, Yasuda K, Suda T, Nakamura H, Chida K. Mycobacterium avium complex disease: prognostic implication of high-resolution computed tomography findings. Eur Respir J 2008 Jul;32(1):147-52. http://doi.org/ 10.1183/09031936.00074207

22. Kim TS, Koh W-J, Han J, Chung MJ, Lee JH, Lee KS, Kwon OJ. Hypothesis on the evolution of cavitary lesions in nontuberculous mycobacterial pulmonary infection: thin-section CT and histopathologic correlation. AJR Am J Roentgenol. 2005 Apr;184(4):1247-52. http://doi.org/ 10.2214/ajr.184.4.01841247

23. Lee G, Lee KS, Moon JW, Koh W-J, Jeong B-H, Jeong YJ, Kim HJ, Woo S. Nodular bronchiectatic Mycobacterium avium complex pulmonary disease. Natural course on serial computed tomographic scans. Ann Am Thorac Soc. 2013 Aug;10(4):299-306. http://doi.org/10.1513/AnnalsATS.201303-0620C

24. Gadkowski LB, Stout JE. Cavitary pulmonary disease. Clin Microbiol Rev. 2008 Apr;21(2):305-33. http://doi.org/10.1128/CMR.00060-07

25. Gafoor K, Patel S, Girvin F, Gupta N, Naidich D, Machnicki S, Brown KK, Mehta A, Husta B, Ryu JH. Cavitary lung diseases: a clinical-radiologic algorithmic approach. Chest. 2018 Jun;153(6):1443-1465. http://doi.org/ 10.1016/j.chest.2018.02.026

26. Strydom N, Gupta SV, Fox WS, Via LE, Bang H, Lee M, Eum S, Shim T, Barry III CE, Zimmerman M. Tuberculosis drugs’ distribution and emergence of resistance in patient’s lung lesions: A mechanistic model and tool for regimen and dose optimization. PLoS Med 2019 Apr 2;16(4):e1002773.http://doi.org/10.1371/journal.pmed.1002773

27. Kwon BS, Lee JH, Koh Y, Kim W-S, Song J-W, Oh Y-M, Lee S-D, Lee SW, Lee J-S, Lim C-M. The natural history of non-cavitary nodular bronchiectatic Mycobacterium avium complex lung disease. Respir Med. 2019 Apr;150:45-50. http://doi.org/ 10.1016/j.rmed.2019.02.007

28. Moon SM, Jhun BW, Baek S-Y, Kim S, Jeon K, Ko R-E, Shin SH, Lee H, Kwon OJ, Huh HJ. Long-term natural history of non-cavitary nodular bronchiectatic nontuberculous mycobacterial pulmonary disease. Respir Med 2019 May;151:1-7. http://doi.org/10.1016/j.rmed.2019.03.014

29. Jhun BW, Jeon K, Eom JS, Lee JH, Suh GY, Kwon OJ, Koh W-J. Clinical characteristics and treatment outcomes of chronic pulmonary aspergillosis. Med Mycol. 2013 Nov;51(8):811-7. http://doi.org/10.3109/13693786.2013.806826

30. Takeda K, Imamura Y, Takazono T, Yoshida M, Ide S, Hirano K, Tashiro M, Saijo T, Kosai K, Morinaga Y. The risk factors for developing of chronic pulmonary aspergillosis in nontuberculous mycobacteria patients and clinical characteristics and outcomes in chronic pulmonary aspergillosis patients
coinfected with nontuberculous mycobacteria. Med Mycol. 2016 Feb;54(2):120-7.
http://doi.org/10.1093/mmy/myv093

Figures

Figure 1
Kaplan–Meier curve according to the presence and size of cavities.